Anavex Life Sciences Corp. (AVXL) may enjoy gains as insiders got busy in the recent days


Anavex Life Sciences Corp.’s filing revealed that its Director Skarpelos Athanasios unloaded Company’s shares for reported $0.45 million on May 25. In the deal valued at $9.06 per share,50,000 shares were sold. As a result of this transaction, Skarpelos Athanasios now holds 1,306,458 shares worth roughly $ 15.01 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Berenberg initiated its Anavex Life Sciences Corp. [AVXL] rating to a Buy in a research note published on Monday, June 23, 2022; the price target was $40. PT values the company’s stock at a premium of 71.28 to its Monday closing price. A number of analysts have revised their coverage, including BTIG Research’s analysts, who began to cover the stock in late September with a ‘”a Buy”‘ rating. H.C. Wainwright also remained covering AVXL and reiterated its “Buy” recommendation on December 16, 2020. Ladenburg Thalmann started covering the stock on September 28, 2020. It rated AVXL as “a Buy”.

Price Performance Review of AVXL

On Monday, Anavex Life Sciences Corp. [NASDAQ:AVXL] saw its stock fall -2.05% to $11.49. On the same session, the stock had its day’s lowest price of $11.42, but rose to a high of $11.99. Over the last five days, the stock has lost -5.59%. Anavex Life Sciences Corp. shares have fallen nearly -33.74% since the year began. Nevertheless, the stocks have fallen -50.04% over the past one year. While a 52-week high of $23.73 was reached on 01/03/22, a 52-week low of $7.13 was recorded on 05/12/22. SMA at 50 days reached $10.52, while 200 days put it at $10.58. A total of 0.68 million shares were traded, compared to the trading of 0.77 million shares in the previous session.

Levels Of Support And Resistance For AVXL Stock

The 24-hour chart illustrates a support level at 11.28, which if violated will result in even more drops to 11.06. On the upside, there is a resistance level at 11.85. A further resistance level may holdings at 12.20. The Relative Strength Index (RSI) on the 14-day chart is 51.43, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.15, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 72.89%. Stochastics %K at 29.20% indicates the stock is a holding.

How much short interest is there in Anavex Life Sciences Corp.?

A steep rise in short interest was recorded in Anavex Life Sciences Corp. stocks on Jul 14, 2022, dropping by -1.24 million shares to a total of 8.26 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 9.5 million shares. There was a decline of -15.01%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 10.98% of the overall stock float, the days-to-cover ratio (short ratio) fell to 7.87.

Anavex Life Sciences Corp. [AVXL] – Who Are The Largest Shareholders?

In filings from BlackRock Fund Advisors, it is revealed that the company now owns 4,822,748 shares, or roughly 6.19% of the outstanding AVXL shares. In other words, the investor’s shares have risen by 34,278 from its previous 13-F filing of 4788470.0. Additionally, SSgA Funds Management, Inc. decreased -19.51% of its stake after which the total value it holdings stand at $46,329,008, while The Vanguard Group, Inc. added 2.84% of its stake to hold $39.36 million in the firm. Over the last quarter, Geode Capital Management LLC purchased 4,385 shares of Anavex Life Sciences Corp., while Morgan Stanley & Co. LLC bought 124,113 shares. At present, Northern Trust Investments, Inc. is holding 712,058 shares valued at $7.35 million. Charles Schwab Investment Managem owned 523,717 shares of the company at the time of its most recent 13F filing, worth $5.4 million.

The most recent change occurred on February 27, 2020 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating.


Please enter your comment!
Please enter your name here